In myeloid cells, a lack of TGFβ signaling decreases tumor size and the number of metastases [22–24], whereas in fibroblasts, decreased TGFβ signaling correlates with poor prognosis in cancer patients [25]. This evidence concerns the gene TGFB1 and neoplasm.